Contrive Datum Insights has published "Continuous Glucose Monitoring Market Size, Share & Industry Analysis, By Component (Sensors, Transmitters, Receivers and Readers, Software and Data Platforms, Insertion and Accessories), Product type (Real-Time CGM (rtCGM), Intermittently Scanned CGM (isCGM / Flash), Professional CGM, Over-the-Counter CGM), Sensor wear duration (Up to 7 Days, 8 to 10 Days, 11 to 15 Days, Beyond 15 Days), Sensing technology (Minimally Invasive Enzymatic Electrochemical, Implantable Fluorescence-Based, Non-Invasive, Microneedle-Based), Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Prediabetes and Metabolic Health, Hospital Glycemic Management), Age group (Pediatric (0 to 17 Years), Adult (18 to 64 Years), Geriatric (65 Years and Above)), Connectivity and integration (Standalone CGM, Integrated with Insulin Pumps, Integrated with Smart Pens, Open-Source and Third-Party Integrated), End user (Home Care Settings, Hospitals, Clinics and Endocrinology Centers, Ambulatory Surgical and Long-Term Care Facilities, Research and Clinical Trial Organizations), Distribution channel (Retail Pharmacies, Online Pharmacies and E-Commerce, Direct-to-Consumer / Manufacturer Direct, Durable Medical Equipment Suppliers, Hospital Pharmacies), Reimbursement status (Public Insurance Reimbursed, Private Insurance Reimbursed, Out-of-Pocket), and Regional Forecast, 2026-2034". The study sizes the global continuous glucose monitoring market at USD 12.8 billion in 2025 and projects growth from USD 15.1 billion in 2026 to USD 36 billion by 2034, a compound annual growth rate of 11.47% across the forecast period.
Continuous glucose monitoring systems measure glucose in interstitial fluid at frequent intervals through the day, using a wearable sensor, a transmitter and a display on a receiver, phone or insulin pump. The category covers sensors, transmitters, readers, software and insertion accessories, sold as real-time, intermittently scanned, professional and over-the-counter products. Buyers are people with diabetes or at risk of it, hospitals, clinics and diabetes centers, and the pharmacies and suppliers that serve them.
Wider reimbursement for Type 2 diabetes and basal insulin users
Wider reimbursement for Type 2 diabetes and basal insulin users is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.47% a year, the component lines exposed to it move fastest: Software and Data Platforms compounds at 17.8%, taking its share of revenue from 12% to 20% and its value from USD 1.536 billion to USD 7.2 billion.
On the upside, the study's bull case assumes large public and private payers extend coverage to most people with Type 2 diabetes, over-the-counter sales grow quickly, and longer-wear sensors lower cost per day enough to widen use in lower-income markets, which would take 2034 revenue to USD 41 billion against the USD 36 billion base case.
The downside is specific. Coverage expansion stalls, tender pricing cuts net price per sensor faster than volume grows, and a sensor safety action or supply interruption slows adoption in the largest markets, and 2034 revenue lands at USD 26 billion. Sensors is the drag, 52% of the 2025 base compounding at 11% while the market runs at 11.47%.
Sensors Scale Against Software and Data Platforms Momentum
The component axis, not the regional one, is what divides the field. Sensors is the volume position, 52% of 2025 revenue at USD 6.656 billion, holding 50% through 2034, and it is defended by scale. Software and Data Platforms is the growth position at 17.8%, and it is open. Strength in one does not carry into the other.
Other Findings in the Study
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Product type | Real-Time CGM (rtCGM) | 68% · USD 8.704 billion | Over-the-Counter CGM 24.6% |
| Sensor wear duration | 8 to 10 Days | 42% · USD 5.376 billion | Beyond 15 Days 26.7% |
| Sensing technology | Minimally Invasive Enzymatic Electrochemical | 90.5% · USD 11.584 billion | Non-Invasive 36.9% |
| Application | Type 1 Diabetes | 58% · USD 7.424 billion | Prediabetes and Metabolic Health 26.7% |
| Age group | Adult (18 to 64 Years) | 63% · USD 8.064 billion | Geriatric (65 Years and Above) 13.9% |
| Connectivity and integration | Standalone CGM | 52% · USD 6.656 billion | Integrated with Smart Pens 17.8% |
| End user | Home Care Settings | 72% · USD 9.216 billion | — |
| Distribution channel | Retail Pharmacies | 38% · USD 4.864 billion | Online Pharmacies and E-Commerce 18% |
| Reimbursement status | Private Insurance Reimbursed | 44% · USD 5.632 billion | Public Insurance Reimbursed 13.7% |
- Regionally, the lead sits with North America: 45% of 2025 global revenue, USD 5.76 billion rising to USD 14.04 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22% in 2025 to 30% in 2034, with revenue growing from USD 2.816 billion to USD 10.8 billion.
- Middle East and Africa remains the smallest region throughout, at 4.5% of 2025 revenue and 4% by 2034.
- By component, the largest line in 2025 was Sensors, at 52% of revenue and USD 6.656 billion.
- The fastest component line is Software and Data Platforms, forecast to compound at 17.8% through the period.
- The United States is the largest single country market at USD 5.1 billion in 2025, 39.84% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across ten axes: by component, and by product type, sensor wear duration, sensing technology, application, age group, connectivity and integration, end user, distribution channel and reimbursement status. The headline total carries bear, base and bull cases at USD 26 billion and USD 41 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.